Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEACON-IPF trial of bexotegrast in idiopathic pulmonary fibrosis
NL-OMON60162Phase 3Completed
- Sponsor
- Pliant Therapeutics
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing Bexotegrast with Placebo (2 arms). Primary endpoint: Change from baseline in absolute forced vital capacity. Started Jul 2024; status: completed.
02
Drugs
bexotegrast
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NL-OMON60162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60162.